NYSE: SPNTSiriuspoint Ltd Stock
$18.20+0.01 (+0.05%)
Updated Oct 31, 2025
SPNT Price
$18.20
Fair Value Price
N/A
Market Cap
$2.13B
52 Week Low
$12.78
52 Week High
$21.03
P/E
10.96x
P/B
0.96x
P/S
0.74x
PEG
0.6x
Dividend Yield
N/A
Revenue
$2.84B
Earnings
$198.30M
Gross Margin
46.7%
Operating Margin
11.52%
Profit Margin
6.4%
Debt to Equity
4.64
Operating Cash Flow
$237M
Beta
0.76
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SPNT Overview
SiriusPoint Limited is an insurer and reinsurer with over $3 billion in total capital. It underwrites businesses and provide solutions to clients and brokers in 150 countries. The company's offerings and distribution capabilities are strengthened by partnerships with Managing General Agents and technology-driven insurance services companies within the Insurance & Services segment. SiriusPoint was incorporated in 2011 and is headquartered in Pembroke, BM.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SPNT's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Reinsurance Insurance
Industry Rating
A
SPNT
Ranked#1 of 7
Ranked#1 of 7
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $23.67 | B | |
| $182.46 | C | |
| $254.09 | C |
Be the first to know about important SPNT news, forecast changes, insider trades & much more!
SPNT News
Overview
Due Diligence Score
–
Industry Average (32)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SPNT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SPNT ($18.20) is trading below its intrinsic value of $21.20, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SPNT is good value based on its earnings relative to its share price (10.96x), compared to the US market average (41.56x)
P/E vs Market Valuation
SPNT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more SPNT due diligence checks available for Premium users.
Valuation
SPNT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
10.96x
Industry
14.19x
Market
41.56x
SPNT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
SPNT is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
SPNT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.96x
Industry
0.98x
SPNT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SPNT price to earnings growth (PEG)
For valuing profitable companies with growth potential
SPNT is good value based... subscribe to Premium to read more.
PEG Value Valuation
SPNT's financial health
Profit margin
Revenue
$755.9M
Net Income
$90.8M
Profit Margin
11.5%
SPNT's Earnings (EBIT) of $327.60M... subscribe to Premium to read more.
Interest Coverage Financials
SPNT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$12.5B
Liabilities
$10.2B
Debt to equity
4.64
SPNT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SPNT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$155.6M
Investing
-$330.9M
Financing
-$6.6M
SPNT's operating cash flow ($236.50M)... subscribe to Premium to read more.
Debt Coverage Financials
SPNT vs Reinsurance Insurance Stocks
Siriuspoint Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.